Catalio Capital Management LP Has $13.29 Million Stock Holdings in Abivax SA Sponsored ADR $ABVX

Catalio Capital Management LP cut its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 39.2% during the fourth quarter, HoldingsChannel reports. The fund owned 98,514 shares of the company’s stock after selling 63,627 shares during the quarter. Abivax comprises approximately 2.5% of Catalio Capital Management LP’s holdings, making the stock its 17th biggest position. Catalio Capital Management LP’s holdings in Abivax were worth $13,285,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. EverSource Wealth Advisors LLC increased its stake in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after acquiring an additional 369 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in Abivax by 661.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after buying an additional 344 shares during the last quarter. T. Rowe Price Investment Management Inc. acquired a new position in Abivax during the fourth quarter worth $61,000. WPG Advisers LLC increased its position in Abivax by 125.9% during the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after buying an additional 253 shares during the last quarter. Finally, Union Bancaire Privee UBP SA acquired a new position in Abivax during the fourth quarter worth $67,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Oddo Bhf reissued an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Morgan Stanley lowered their target price on shares of Abivax from $145.00 to $132.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 2nd. Wedbush raised shares of Abivax from an “underperform” rating to a “neutral” rating and lowered their target price for the stock from $110.00 to $90.00 in a research report on Tuesday, June 2nd. BTIG Research reissued a “buy” rating and set a $150.00 target price on shares of Abivax in a research report on Tuesday. Finally, Jefferies Financial Group downgraded shares of Abivax from a “buy” rating to a “hold” rating and lowered their target price for the stock from $160.00 to $90.00 in a research report on Tuesday, June 2nd. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Abivax currently has an average rating of “Moderate Buy” and an average price target of $130.08.

Abivax Stock Performance

Shares of NASDAQ:ABVX opened at $100.15 on Thursday. The company has a market cap of $7.99 billion, a P/E ratio of -19.22 and a beta of 0.69. The stock’s 50-day moving average is $114.81 and its 200-day moving average is $118.49. Abivax SA Sponsored ADR has a 52-week low of $5.69 and a 52-week high of $148.83.

Abivax (NASDAQ:ABVX) last released its earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.23. The company had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. As a group, equities analysts predict that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.